Findings

What do systematic reviews say?

3,454 questions · 3,562 findings · 816 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 538 · 15.1%GRADE not reported 239 · 6.7%Very low 933 · 26.2%Low 1,041 · 29.2%Moderate 612 · 17.2%High 199 · 5.6%

Febuxostat 120 mg/day vs allopurinol

Pain · people with chronic gout

The review found no eligible studies for this question.

1 finding from 1 review

Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Febuxostat 120 mg/day vs allopurinol

Patient global assessment · people with chronic gout

The review found no eligible studies for this question.

1 finding from 1 review

Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Febuxostat 120 mg/day vs allopurinol

Health related quality of life · people with chronic gout

The review found no eligible studies for this question.

1 finding from 1 review

Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Febuxostat 120 mg/day vs allopurinol

Serious adverse events · people with chronic gout

Febuxostat 120 mg/day showed no clear difference in serious Adverse Events compared with allopurinol (high certainty).

1 finding from 1 review

Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
RR 1.2 [0.7, 1.93]
3 studies · 1041 participants
High

Febuxostat 120 mg/day vs allopurinol

Withdrawals due to adverse events · people with chronic gout

Febuxostat 120 mg/day showed no clear difference in discontinuations due to adverse events compared with allopurinol (high certainty).

1 finding from 1 review

Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
RR 1.6 [0.49, 5]
3 studies · 1041 participants
High

ULTRA LOW DOSE (<2 mg/day) vs ANY DOSE ‐ short term

Leaving the study early: any reason ‐ when compared with high dose ( greater than or equal to 10 mg) · patients with schizophrenia

ULTRA LOW DOSE (<2 mg/day) showed no clear difference in leaving the study early: Any reason ‐ when compared with high dose… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 0.94 [0.72, 1.23]
1 study · 679 participants
Moderate

ANY INTERMITTENT DRUG TECHNIQUE vs MAINTENANCE THERAPY

Relapse · patients with schizophrenia

It is very uncertain whether INTERMITTENT (DRUG HOLIDAY) changes relapse: long term (+ 26 weeks) as defined in each study compared with MAINTENANCE THERAPY (very low certainty).

1 finding from 1 review

Intermittent drug techniques for schizophrenia 2013 · Cochrane Headline outcomes only
RR 1.7 [0.54, 5.38]
2 studies · 61 participants
Very low

ANY INTERMITTENT DRUG TECHNIQUE vs MAINTENANCE THERAPY

Hospital admissions · patients with schizophrenia

It is very uncertain whether INTERMITTENT (DRUG HOLIDAY) changes hospitalisation: medium term (13‐25 weeks) as defined in each study compared with MAINTENANCE THERAPY (very low certainty).

1 finding from 1 review

Intermittent drug techniques for schizophrenia 2013 · Cochrane Headline outcomes only
RR 0.26 [0.03, 2.14]
1 study · 35 participants
Very low

ANY INTERMITTENT DRUG TECHNIQUE vs MAINTENANCE THERAPY

Global state: average score: long term (+ 26 weeks) Global Assessment Scale (GAS). Scale from: 0 to 100. · patients with schizophrenia

1 finding from 1 review

Intermittent drug techniques for schizophrenia 2013 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

ANY INTERMITTENT DRUG TECHNIQUE vs MAINTENANCE THERAPY

Mental state · patients with schizophrenia

1 finding from 1 review

Intermittent drug techniques for schizophrenia 2013 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

ANY INTERMITTENT DRUG TECHNIQUE vs MAINTENANCE THERAPY

Adverse effects: tardive dyskinesia: long term (+ 26 weeks) as defined in each study · patients with schizophrenia

It is very uncertain whether INTERMITTENT (DRUG HOLIDAY) changes adverse effects: tardive dyskinesia: long term (+ 26 weeks) as… compared with MAINTENANCE THERAPY (very low certainty).

1 finding from 1 review

Intermittent drug techniques for schizophrenia 2013 · Cochrane Headline outcomes only
RR 1.64 [0.82, 3.3]
2 studies · 50 participants
Very low

ANY INTERMITTENT DRUG TECHNIQUE vs MAINTENANCE THERAPY

Cost‐effectiveness · patients with schizophrenia

1 finding from 1 review

Intermittent drug techniques for schizophrenia 2013 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

ANY INTERMITTENT DRUG TECHNIQUE vs MAINTENANCE THERAPY

Leaving the study early/ loss to · patients with schizophrenia

It is very uncertain whether INTERMITTENT (DRUG HOLIDAY) changes leaving the study early/ loss to compared with MAINTENANCE THERAPY (very low certainty).

1 finding from 1 review

Intermittent drug techniques for schizophrenia 2013 · Cochrane Headline outcomes only
RR 1.01 [0.46, 2.2]
2 studies · 62 participants
Very low

Acupuncture on the day of ET vs control

Live birth rate · women undergoing assisted reproduction

Acupuncture on the day of ET showed no clear difference in live birth rate compared with control (low certainty).

1 finding from 1 review

Acupuncture and assisted reproductive technology 2013 · Cochrane Headline outcomes only
OR 1.22 [0.87, 1.7]
8 studies · 2505 participants
Low

Summary of findings: 5 mg/day vs placebo

Benefits · rotator cuff disease

The review found no eligible studies for this question.

1 finding from 1 review

Topical glyceryl trinitrate for rotator cuff disease 2009 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: 5 mg/day vs injection with corticosteroid and anaesthetic

Benefits · rotator cuff disease

The review found no eligible studies for this question.

1 finding from 1 review

Topical glyceryl trinitrate for rotator cuff disease 2009 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: 5 mg/day vs injection with corticosteroid and anaesthetic

Pain ‐ not reported1 · rotator cuff disease

The review found no eligible studies for this question.

1 finding from 1 review

Topical glyceryl trinitrate for rotator cuff disease 2009 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: 5 mg/day vs injection with corticosteroid and anaesthetic

Function ‐ not measured · rotator cuff disease

The review found no eligible studies for this question.

1 finding from 1 review

Topical glyceryl trinitrate for rotator cuff disease 2009 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: 5 mg/day vs injection with corticosteroid and anaesthetic

Harms · rotator cuff disease

The review found no eligible studies for this question.

1 finding from 1 review

Topical glyceryl trinitrate for rotator cuff disease 2009 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: 5 mg/day vs injection with corticosteroid and anaesthetic

Headache · rotator cuff disease

It is very uncertain whether summary of findings: 5 mg/day changes headache ( compared with injection with corticosteroid and anaesthetic (very low certainty).

1 finding from 1 review

Topical glyceryl trinitrate for rotator cuff disease 2009 · Cochrane Headline outcomes only
RR 31.003 [1.96, 490.31]
1 study · 48 participants
Very low